Printer Friendly

MICROPROBE NAMES VICE PRESIDENT SALES & MARKETING

 BOTHELL, Wash., June 24 /PRNewswire/ -- MicroProbe Corp., based here, today announced that Allan G. Cochrane has been named vice president of sales and marketing of the company's diagnostics division.
 Cochrane, 40, brings to MicroProbe more than 18 years of senior sales and marketing experience in the domestic and international diagnostics markets. Prior to joining MicroProbe, he was vice president of sales and marketing at Detroit-based Difco Laboratories, a privately held leading manufacturer of diagnostic and laboratory products for microbiology. Cochrane joined Difco in 1975 as a technical sales representative and rose through the managerial ranks, ultimately responsible for all of Difco's sales and marketing activities with 120 employees and an annual budget in excess of $14 million.
 Among Cochrane's most recent accomplishments, in 1991 he established a business unit in Germany with sales, marketing and distribution activities, currently employing 25 people with retail sales of $4 million. In 1992, he established the Difco Microbiology Division, a direct sales, marketing and service organization of automated microbiology instruments.
 As Difco's director of business development, Cochrane was responsible for all strategic alliance development and successfully negotiated a major joint venture with the diagnostics firm of Amersham PLC to develop rapid industrial assays. In addition, he arranged nine OEM transactions and completed a technology license agreement with several diagnostics firms. Cochrane received a bachelor of science degree in biology from Roberts Wesleyan College.
 Through its diagnostic division, MicroProbe is the first company to bring the benefits of nucleic-acid probe technology directly to the physician's office. The company makes diagnostic systems for the rapid and simultaneous identification of infectious disease organisms from a single-patient sample. Currently sold in the United States, the company's Affirm(TM) VP System detects the presence of Trichomonas vaginalis and Gardnerella vaginalis, organisms associated with vaginitis.
 Founded in 1985, MicroProbe Corp. is developing practical applications of oligonucleotides for the diagnosis and treatment of infectious diseases, utilizing proven principles of biochemical control. In addition to producing nucleic acid probe-based systems for the rapid identification of infectious-disease microorganisms, MicroProbe is involved in research aimed at the discovery and development of new classes of therapeutics that selectively block genes and disease-causing proteins of chronic viral infections and certain cancers.
 -0- 6/24/93
 /CONTACT: John L. Bishop, chairman and chief executive officer of MicroProbe, 206-485-8566/


CO: MicroProbe Corp. ST: Washington IN: MTC SU: PER

GT-SG -- SJ001 -- 5158 06/24/93 08:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 24, 1993
Words:399
Previous Article:EMONS HOLDINGS OMITS PREFERRED DIVIDEND
Next Article:ALLIED ANNOUNCES THE CLOSING OF TWO ACQUISITIONS AND A DEFINITIVE AGREEMENT FOR THE PURCHASE OF A THIRD LABORATORY COMPANY
Topics:


Related Articles
MICROPROBE RECEIVES $2.9 MILLION INVESTMENT
MICROPROBE AWARDED SBIR GRANT TO EVALUATE RAPID TEST FOR ANTIBIOTIC RESISTANCE
MICROPROBE CORPORATION NAMES CEO AND PRESIDENT, COO
JON SAXE AND DR. FRED CRAVES JOIN INCYTE'S BOARD OF DIRECTORS
MICROPROBE AWARDED NIH GRANT FOR ANTIBIOTIC-RESISTANT TUBERCULOSIS DETECTION PROGRAM
MICROPROBE AND PROCTER & GAMBLE SIGN ORAL CARE PRODUCT AGREEMENT
MICROPROBE SIGNS BINDING AGREEMENT TO SELL DIAGNOSTICS BUSINESS
MICROPROBE COMPLETES THE SALE OF ITS DIAGNOSTIC BUSINESS
Harvey J. Hoyt, MD appointed CEO of Response Biomedical

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters